Share This Article:

Comparison between Different Modalities of Treatment of Ewing Sarcoma

Abstract Full-Text HTML Download Download as PDF (Size:119KB) PP. 69-72
DOI: 10.4236/ojo.2012.22014    3,149 Downloads   5,639 Views  

ABSTRACT

Background: Ewing sarcoma is the most common primary malignant tumour in patients younger than 10 years of age. The incidence is less than 1 per 1 million per year. Usually it is located in the diaphysis of long bones. Prognosis of these tumours has improved dramatically since the introduction of multi-agent chemotherapy, from an erstwhile 10% survival rate to the current 70% for patients with non-metastatic Ewing sarcoma. Method: A retrospective review of patients with histologically confirmed Ewing sarcoma who were treated in the Department of Orthopaedics, B.S. Medical College during the time period from April 2000 to March 2012 was performed. Patients were divided into two groups: Group A included those treated by External Beam Radiotherapy (EBRT) + chemotherapy while Group B included the patients treated with surgery + chemotherapy. Results were analysed depending on the survival rates. Kaplan-Meier survival curves were compared using log-rank test and a multivariate Cox proportional hazards model was calculated. Result: The survival curves of both the groups were not found to be significantly different. Conclusion: Treatment of Ewing tumour has multiple options. No one treatment modality is superior. Survival rates of patients treated by radiation + chemotherapy are not significantly different from those treated with surgery + chemotherapy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

R. Bandyopadhyay, A. Mukherjee and U. Bhakat, "Comparison between Different Modalities of Treatment of Ewing Sarcoma," Open Journal of Orthopedics, Vol. 2 No. 2, 2012, pp. 69-72. doi: 10.4236/ojo.2012.22014.

References

[1] J. Potratz, H. Jürgens, A. Craft and U. Dirksen, “Ewing Sarcoma: Biology-Based Therapeutic Perspectives,” Pediatric Hematology-Oncology, Vol. 29, No. 1, 2012, pp. 12-27. doi:10.3109/08880018.2011.627582
[2] J. Potratz, U. Dirksen, H. Jürgens and A. Craft, “Ewing Sarcoma: Clinical State-of-the-Art,” Pediatric Hematology-Oncology, Vol. 29, No. 1, 2012, pp. 1-11. doi:10.3109/08880018.2011.622034
[3] D. Gulati, A. N. Aggarwal, S. Kumar and S. Chaturvedi, “Primary Ewing’s Sarcoma of the Second Cervical Vertebra: A Rare Entity,” Journal of Pediatric Orthopaedics B, Vol. 20, No. 6, 2011, pp. 408-412. doi:10.1097/BPB.0b013e328345d78a
[4] J. Schrager, R. E. Patzer, P. J. Mink, K. C. Ward and M. Goodman, “Survival Outcomes of Pediatric Osteosarcoma and Ewing’s Sarcoma: A Comparison of Surgery Type within the SEER Database, 1988-2007,” Journal of Registry Man-agement, Vol. 38, No. 3, 2011, pp. 153-161.
[5] S. T. Jung, H. W. Park and J. Y. Chung, “Treatment of a Severe Neglected Valgus Deformity after Excision of the Distal Fibula for Ewing’s Sarcoma,” Journal of Bone and Joint Surgery, Vol. 94, No. 1, 2012, pp. 138-140. doi:10.1302/0301-620X.94B1.27784
[6] C. Müller, C. C. Winter, D. Rosenbaum, J. Boos, G. Gosheger, J. Hardes, et al., “Early Decrements in Bone Density after Completion of Neoadjuvant Chemotherapy in Pediatric Bone Sarcoma Patients,” BMC Musculoskeletal Disorders, Vol. 11, 2010, p. 287.
[7] T. P. Cripe, “Ewing Sarcoma: An Eponym Window to History,” Sarcoma, Vol. 2011, 2011, Article ID 457532.
[8] M. Huang and K. Lucas, “Current Therapeutic Approaches in Metastatic and Recurrent Ewing Sarcoma,” Sarcoma, Vol. 2011, 2011, Article ID 863210.
[9] Y. Funakoshi, T. Mukohara, T. Kataoka, H. Tomioka, N. Chayahara, Y. Fujiwara, et al., “Left Atrial Extension of Metastatic Lung Tumor via Pulmonary Vein: Report on the First Case of Ewing Sarcoma,” Rare Tumors, Vol. 2, No. 3, 2010, p. e53.
[10] S. Hafezi, R. R. Seethala, E. B. Stelow, S. E. Mills, I. T. Leong, E. MacDuff, et al., “Ewing’s Family of Tumors of the Sinonasal Tract and Maxillary Bone,” Head and Neck Pathology, Vol. 5, No. 1, 2011, pp. 8-16. doi:10.1007/s12105-010-0227-x

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.